Burden of disease and risk factors for death among children treated for tuberculosis in Malawi by Flick, et al.
Burden of disease and risk factors for death among children 
treated for tuberculosis in Malawi
Robert J. Flick1,2,3, Maria H. Kim1,4, Katie Simon1,4, Adamson Munthali1, Mina 
Hosseinipour2,5, Nora E. Rosenberg2,5, Peter N. Kazembe1,4, James Mpunga6, and Saeed 
Ahmed1,4
1Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
2University of North Carolina Project-Malawi, Lilongwe, Malawi
3University of Colorado School of Medicine, Denver, United States
4Baylor International Pediatric AIDS Initiative at Texas Children’s Hospital, Baylor College of 
Medicine, Houston, United States
5University of North Carolina at Chapel Hill, Chapel Hill, United States
6Malawi Ministry of Health National Tuberculosis Programme, Lilongwe, Malawi
SUMMARY
SETTING—Tuberculosis is a leading cause of childhood death. There is limited patient-level data 
on pediatric TB in Malawi that can be used to guide programmatic interventions.
OBJECTIVE—To describe pediatric tuberculosis case burden, disease pattern, treatment 
outcomes, and risk factors for death and poor outcome.
DESIGN—We conducted a retrospective cohort study utilizing routinely collected data in 
treatment registers. Odds ratios for factors associated with poor outcome and death were 
calculated separately using generalized estimating equations.
RESULTS—Children represented 8% (371/4,642) of tuberculosis diagnoses. Median age was 
7(IQR 2.8–11) and 32.8%(113/345) were HIV-infected. Of these, 54.0% were on antiretroviral 
therapy (ART) at time of anti-tuberculosis treatment (ATT) initiation, 21.2% started ART during 
ATT, and 24.8% had no documented ART. The treatment success rate was 77.3% (11.2% cured, 
66.1% completed treatment) with 22.7% experiencing a poor outcome (9.5% died, 13.2% were 
lost to follow-up). Being on ART at time of ATT initiation was associated with an increased odds 
of death compared to initiating ART during ATT(aOR=2.75,95%CI 1.27–5.96).
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CONCLUSION—Children represent a small proportion of diagnosed tuberculosis cases and 
experience poor outcomes. Higher odds of death among children already on ART raises concerns 
over the management of these children in routine settings. Further discussion and research is 
warranted on pediatric-specific strategies to improve outcomes among these children.
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INTRODUCTION
Tuberculosis (TB) is a leading cause of childhood death worldwide.1 In high burden settings, 
TB is a common cause of pediatric pneumonia and has been microbiologically confirmed 
post-mortem in a quarter of African children who died while hospitalized.2,3 Treatment 
outcomes remain poor in resource-constrained settings where up to half of children less than 
one year of age who present with advanced disease die.4 However, treatment success rates in 
excess of 90% are possible in developed settings with access to rapid detection and 
treatment initiation.5
Only one-third of the estimated one million cases of TB in children that occurred in 2010 
were reported.6,7 This is in part due to challenges with TB diagnosis in children. These 
include protean clinical presentation, the limited ability of children to produce sputum, and 
paucity of tuberculosis bacilli in samples that are produced.8 Because of the rapid 
progression from infection to clinical disease—typically in less than 12 months—there is a 
limited time window for clinicians to identify children at risk of exposure and those in the 
early stages of disease.8,9 HIV-infected children face unique risks because of the higher rate 
of household exposure to TB, faster progression from infection to disease, and the high 
incidence of other infections that may complicate diagnosis.10,11 Further, countries with the 
highest burden of tuberculosis have limited diagnostic capacity, usually relying on sputum 
microscopy, a test with low sensitivity in the few children who can produce specimens.12
Planning effective child-focused TB interventions requires detailed evidence to guide 
implementation, however patient-level data is often scarce. In Malawi, a resource-limited 
landlocked country of 16 million people in sub-Saharan Africa, the most recent published 
data describes pediatric TB from 1998, before the rollout of HIV diagnosis and treatment 
services and decentralization of TB treatment.13 In preparation for a community health 
worker-based intervention, we conducted a pre-intervention assessment to describe the 
pediatric TB case burden, disease pattern, treatment outcomes, and risk factors for poor 
outcome and death.
STUDY POPULATION AND METHODS
Study design and setting
We conducted a retrospective cohort study utilizing routinely collected programmatic data in 
Malawi Ministry of Health (MOH) treatment registers at ten health facilities (six hospitals, 
four health centers) in Malawi’s central region with a total estimated catchment area 
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population in 2012 of 742,000 (4.6% of the national population).14 Children under 15 years 
of age comprise 49% of this population.15 Pertinent health indicators in the central region 
are similar to the rest of the country, however the southern region is an important outlier 
apropos HIV prevalence, where estimated HIV prevalence is roughly twice as high as the 
central (14.5% vs 7.6%) and northern (6.6%) regions.15
The facilities surveyed serve diverse settings, from peri-urban to rural, and all are the site of 
a community health worker-based outreach program called Tingathe that has been described 
elsewhere.16,17 Hospitals and health centers vary primarily by the concentration of 
infrastructure and experienced personnel—hospitals often have at least one medical doctor 
on staff, and may have access to chest radiography, whereas health centers typically do not.
Half of all people living with HIV in Malawi are on antiretroviral therapy (ART), but only 
one-quarter of HIV-infected children are on treatment.18 The annual incidence rate of TB is 
estimated at 227 cases per 100,000, and approximately half of all TB patients in Malawi are 
HIV-infected.19
Diagnosis and management of TB and HIV in children
A case of pediatric TB was defined as any person less than 15 years of age recorded in a TB 
treatment register. Malawi National Tuberculosis Program (NTP) guidelines recommend a 
flexible approach to the diagnosis of TB in children that incorporates findings from physical 
examination, patient history, chest radiography, and/or sputum smear microscopy.20 Smear 
microscopy was the only microbiological test widely available during the study period. A 
diagnosis of TB is most commonly made by clinical officers and nurses. After diagnosis, 
health surveillance assistants dispense medication, assess adherence, screen for adverse 
effects and treatment failure, and trace household contacts. Individuals diagnosed with TB 
are managed on at outpatient basis when possible, with monthly facility visits of medication 
refills.
Standard anti-tuberculosis treatment (ATT) for patients newly diagnosed with pulmonary TB 
is per Malawi MOH and WHO guidelines: a two month intensive phase of isoniazid, 
rifampicin, pyrazinamide, and ethambutol, followed by a four month continuation phase of 
isoniazid and rifampicin.20,21 All patients started on ATT are referred for HIV counseling 
and testing, with ART initiated within two weeks for HIV-infected patients. All TB and HIV 
care is provided free of charge and is decentralized to the health center level. Every 
individual who receives ATT is recorded in a TB treatment register, along with their 
demographic information, and details of their diagnosis and course of treatment. 
Standardized treatment outcomes are recorded for every patient (Box 1). Children under five 
years who live in the same household as an individual diagnosed with pulmonary TB are 
eligible for a six-month course of isoniazid preventive therapy.
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Box 1
Standardized definitions of treatment outcomes*
Term Definition
Cured A patient with positive smear or culture results at ATT initiation whose results are 
negative in the last month of ATT and on at least one prior occasion
Treatment completed A patient with negative or unavailable smear or culture results at the beginning of 
treatment who finished a full course of ATT
Treatment Success† Sum of patients with outcomes “Cured” and “Treatment completed”
Died A patient who dies for any reason while receiving ATT
Lost to follow-up‡ A patient whose ATT was interrupted for two months or more
Poor outcome† Sum of patients with outcomes “Died” or “Lost to follow-up”
Transferred Out¶ A patient who was transferred to another treatment facility for ATT
*ATT denotes anti-TB treatment
†Summary outcomes generated for analysis
‡
Includes patients with no recorded outcome two months after anticipated date of treatment completion
¶
Excluded from outcomes analysis
Data collection and analysis
Facilities were visited during June-August 2013. TB treatment registers maintained by MOH 
TB officers containing records for patients initiating ATT were scanned, de-identified, and 
entered into a Microsoft Excel database. Data from 1 January 2011 through the date of 
facility visit was used for all analyses except annual incidence estimates. These calculations 
used a subset of data (January – December 2012) as this time period contained the most 
complete records. The number of pediatric cases documented in TB treatment registers and 
projections for health facility catchment area population was used for this analysis.22
Outcomes analysis
Patients with no documented outcome more than two months after the anticipated treatment 
completion date were presumed to have been lost to follow-up (LTFU). Patients who 
transferred out and those who were still on treatment at time of data abstraction were 
excluded from outcomes analysis. A summary outcome measure, “treatment success”, was 
created that combined patients who were cured or completed treatment (Figure 1). Two 
separate analyses were then conducted. One combined patients who experienced death or 
LTFU into a summary category, “poor outcome”, and compared against patients with 
treatment success. Because of potential bias introduced by the presumption of LTFU status 
for patients with no documented outcome, we conducted a second analysis comparing only 
patients who died to those with treatment success.
Analysis was conducted using a preset significance level of 0.05. Pearson’s Χ2 and Fisher’s 
exact tests tests were used to compare differences in categorical variables, and two-tailed 
student’s t-tests were used to compare continuous variables. Odds ratios (OR) with 95% 
confidence intervals (95% CI) and robust standard errors were calculated using generalized 
estimating equations with logit link and exchangeable correlation matrix to account for 
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correlation between observations at the same site. Multivariate analysis was conducted using 
a backward elimination approach. For each exposure-outcome variable pairing, a directed 
acyclic graphs (DAG) was drawn. All factors identified as potential confounders from each 
paring’s DAG were included in a preliminary model. Potential confounders were then 
eliminated step-wise, with variables retained at a p-value of 0.05. This approach allowed 
distinct models to be generated for each independent variable to produce adjusted odds 
ratios (aOR). Kaplan-Meier curves were generated for survival analysis with death as the 
primary outcome. All analysis was done using Stata Special Edition, version 14.1(Stata-
Corp LP, College Station, TX, USA).
Ethics
The study was approved by the Malawi National Health Science Research Committee and 
the Baylor College of Medicine Institutional Review Board.
RESULTS
Burden of pediatric TB
From January 2011 through date of facility visit, 4,642 patients were treated for TB, of 
whom 371 (8.0%) were children. The proportion of children among all TB cases varied 
across facilities and over time (median=7.9%, interquartile range [IQR] 2.7–8.3; Figure 2). 
One facility did not record any pediatric patients. District hospitals demonstrated a higher 
proportion of pediatric cases compared to other facilities (9.3% vs 3.3%, p=0.007). 
Bacteriologic confirmation was rare (10.2%). Between January and December 2012, 2,111 
individuals (199 children, 1,912 adults) were diagnosed with TB, representing 10.4% of 
Malawi’s total number of case notifications. The age-specific annual incidence rate for this 
period was 56 per 100,000 for children and 496 per 100,000 for adults (Table 1).
Characteristics of children treated for TB
The majority (63.1%, 234/371) of pediatric patients were in the 5–14 age group (median 
age=7, IQR 2.8–11) and were male (54.7%, 203/371; Table 2). All patients were newly 
treated except for eight who had relapsed and two who had missing data. The type of TB 
varied significantly according to age category. Smear-negative pulmonary TB was the most 
common type (47.4%) followed by extrapulmonary TB (EPTB; 42.3%). Smear-positive 
pulmonary TB was rare (10.2%) and was only documented in the 5–14 year age group. Of 
the 144 patients treated for EPTB with site of involvement recorded, lymph node 
involvement was most common (36.8%), followed by pleural (20.8%), vertebral (16.7%), 
and pericardial (16.0%) involvement (Table 3). No miliary TB was recorded.
HIV prevalence
Most children treated for TB had known HIV status (347/371, 93.5%). Of these, 32.6% 
(113/347) were HIV-infected. Of 347 children with known status, most (57.1%) had been 
tested before ATT initiation, 36.9% were tested after their TB diagnosis, and 6.1% had 
unknown HIV test timing. 6.5% (24/347) of children had unknown HIV status, and of these, 
7/24 were documented as having unknown serostatus whereas the remainder were missing 
any documentation. More than half (54.0%, 61/113) were already on ART at the time of 
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ATT initiation, 21.2% started ART during ATT, and 24.8% had no documented ART. 
Children who were already on ART at the time of TB diagnosis were older than those not on 
ART (mean age 7.4 vs 6.0, p=0.034)
Outcomes
Of the 371 children treated for TB, 72 were still on ATT at time of data collection and four 
transferred out. The 295 remaining children were included in the outcomes analysis. Of the 
295, 77.3% were treated successfully(11.2% cured, 66.1% completed treatment) and 22.7% 
experienced a poor outcome(9.5% died, 13.2% LTFU). Children less than one year had a 
significantly lower proportion of poor outcome (19.0%, p<0.001). Children older than five 
years had a significantly higher proportion of death (10.8%, p<0.001)
Risk factors for poor outcome vs treatment success
Smear-positive TB was associated with decreased odds of poor outcome (aOR=0.12, 95% 
CI 0.02–0.76, Table 4) compared to smear-negative and EPTB when adjusting for age and 
HIV status. Among EPTB patients with documented anatomic site of involvement, 
pericardial (aOR=4.07, 95% CI 1.65–10.05) and pleural (aOR=3.60, 95% CI 1.35–9.62) 
involvement were associated an increased adjusted odds of poor outcome compared to 
patients with lymph node involvement when adjusting for age, sex, and HIV status.
Risk factors for death vs treatment success
Children already on ART at time of ATT initiation experienced an increased odds of death 
compared to those who initiated ART during ATT after controlling for age, type of TB, and 
sex (aOR=2.75, 95%CI 1.27–5.96). The majority of deaths in this group occurred within the 
first two months of ATT (Figure 3). Age between 1–4 years was associated with decreased 
odds of death after adjusting for HIV status and type of TB (aOR=0.53, 95% CI 0.29–0.96). 
Among EPTB patients, pericardial (aOR=15.21, 95%CI 1.36–169.50) and pleural 
involvement (aOR=13.55, 95%CI 1.63–112.7) were associated with an increased adjusted 
odds of death when controlling for HIV status, however with wide confidence intervals.
DISCUSSION
This study is the first in over a decade, and notably the first in the era of widely available 
HIV diagnosis and treatment, to describe patient-level data on pediatric tuberculosis 
diagnosis and management under operational conditions in Malawi. Importantly, these 
findings suggest children make up a low proportion of all patients treated for TB (8%) and 
that children already on ART at time of ATT initiation have a higher odds of death.
The burden of pediatric TB is primarily a function of the burden of TB among adults, who 
are usually the source of disease. In countries with complete modeling data that are similar 
in demography and incidence rate—notably Tanzania and Uganda—the true proportion of 
all TB cases that occur in children exceeds 15%.23 An even lower proportion of all patients 
treated for TB were children in this study compared to some previous work (8% vs 11.9%), 
despite an increase in the proportion of the total population who are children.13,24,25 Even at 
hospitals, which are arguably best equipped to diagnose TB in children, the proportion of 
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pediatric cases was just 9.3%. It is therefore likely that given the demographics and high 
prevalence of TB among adults the 8% proportion reflects gaps in the effectiveness of case-
finding in children. The greatest number of cases occurred in the 5–14 year age group. This 
age category is typically defined by lower rates of TB,8 suggesting under diagnosis in 
children less than five years.
Major changes in TB service delivery may further explain the decrease in children as a 
proportion of all TB cases. Diagnosis and treatment services have been decentralized from 
43 district and central hospitals in 1998 to almost 700 hospitals and health centers in 2013. 
The greater lab, radiologic, and clinical capacity found in district and central hospitals may 
allow these facilities to more frequently establish a diagnosis of TB in children compared to 
health centers. The nearly three-fold higher proportion of pediatric cases observed in district 
hospitals supports this hypothesis (9.3% vs 3.3%, p=0.007), as do other studies.13 Therefore 
the 8% proportion observed in this study may reflect a preferential increase in adult case-
finding at the peripheral facilities that began offering these services in the last decade.
The relatively high proportion of children with unknown HIV status (6.5%) is troubling and 
suggests that provider-initiated testing and counseling (PITC) is still not universal at one of 
the most critical points for HIV screening. Further, this finding is unlikely to be simply a 
relic of missing documentation as almost one-third of patients had their status actively 
recorded as unknown. This finding corroborates other work in Malawi’s central region 
demonstrating suboptimal HIV testing coverage rates at high-yield service delivery points.26
The overall treatment success rate was 77.3%, higher than the previously reported rate of 
45% but short of the WHO target of 85%.13 In stark contrast to past studies, we did not find 
an association between HIV status and poor outcome or death, suggesting this improvement 
is likely due to greatly expanded access to HIV diagnosis and treatment services.27 While 
this drastic improvement is commendable, factors associated with death warrant further 
investigation.
The increased odds of death in HIV-infected children already on ART is particularly 
troubling. ART status remained strongly associated with death even after controlling for 
multiple potential confounders. Importantly, the finding remained robust in the death 
analysis that excluded children with missing data, reducing the likelihood of bias introduced 
by incomplete records. Among patients with outcome timing available, deaths tended to 
occur during the first two months of ATT (Figure 3). The most likely etiology of this finding 
depends on whether these patients were recently initiated on ART, or had been on long-term 
treatment before death. Early mortality due to advanced disease at presentation is well 
described for patients early in their ART course.28 Additionally, new TB cases may 
represent TB unmasking IRIS that may be associated with higher mortality.29
Among children on long term ART, virological failure (VF) is a major concern. VF is 
significantly more prevalent and harder to detect in children compared to adults. Up to one 
in five children experience VF within three years of ART initiation, with exposure to 
nevirapine-based regimens (such as the first-line pediatric regimen in Malawi), poor 
adherence, and adolescence associated with increased risk.30–32
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Caution is warranted in interpreting the increased odds of death in HIV-infected children 
already on ART, especially given the dataset’s lack of detailed ART versus ATT initiation 
time, the retrospective nature of the study, and the low rates of bacteriological confirmation 
that may have led to misdiagnosis of TB. What is clear however is children on ART who are 
diagnosed with TB in routine settings die at higher rates compared to patients who newly 
initiate ART. Incident TB in these children, regardless of etiology, should prompt more 
intensive clinical investigation. Additional work is needed to understand the true etiology of 
this association, and to design services that meet the unique needs of HIV-infected children 
on ART. Given the additive impact of IPT among patients with early ART in reducing rates 
of severe illness from TB and other pathogens, its potential as a treatment strategy among 
HIV-infected children on ART warrants discussion.33
EPTB was far more common than previously reported in Malawi.13,34 This should be 
interpreted with caution as no EPTB cases were microbiologically confirmed. Distribution 
of EPTB by anatomic site largely corresponded with what has previously been reported, 
with lymph, pleural, and vertebral predominating. Of note is the lack of miliary TB, however 
this may be a reflection of limited use of chest radiography or incomplete reporting. The 
relatively low number of patients with TB meningitis may reflect high BCG coverage in 
Malawi or challenges in the diagnosis of TB meningitis.35
Several limitations additional to those mentioned above are important to recognize. First, our 
estimates for annual incidence rates rely heavily on projections of facility catchment area 
population that are open to scrutiny. Second, our use of routine program data introduces 
greater possibility for documentation errors compared to a controlled setting. However, we 
feel this approach was necessary to best ascertain the current state of pediatric TB 
management at public facilities. Further, our major risk factors were associated with death, 
and this analysis excluded missing records thereby minimizing any adverse impact of 
missing data on our results.
CONCLUSIONS
The proportion of pediatric TB among notified cases is 8% and lower than expected given 
established TB incidence rate and population demographics. Treatment outcomes, while 
improved in the era of HIV diagnosis and treatment services, remain poor with more than 
one in five children experiencing a poor outcome. Children already on ART at time of ATT 
initiation are more likely to die compared to those who initiate ART during ATT. There is an 
urgent need for pediatric-specific strategies for intensified case finding and improved 
management of HIV-infected children on ART. Given the success of community health 
worker-driven interventions in addressing pediatric HIV in this setting,16,17,36 we are using 
this data to integrate pediatric TB case-finding and management into an existing community 
health worker focused intervention.
Acknowledgments
This study was made possible by the Tingathe program supported by USAID cooperative agreement number 674-
A-00-10-00093-00. M.H.K. was supported by the Fogarty International Center of the National Institutes of Health 
(NIH) under award number K01 TW009644. R.F. was supported by NIH Research Training Grant number R25 
Flick et al. Page 8
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2017 February 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
TW009340 funded by the Fogarty International Center. The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript. The authors thank Tony Harries for his mentorship in 
developing the research concept and for his critical review of the manuscript. The authors also thank the Ministry of 
Health staff members who provided critical assistance with primary data collection, and who work tirelessly to care 
for adults and children with TB in Malawi.
References
1. Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis. 
2010; 50(S3):S184–S194. DOI: 10.1086/651490 [PubMed: 20397947] 
2. Oliwa JN, Karumbi JM, Marais BJ, Madhi SA, Graham SM. Tuberculosis as a cause or comorbidity 
of childhood pneumonia in tuberculosis-endemic areas: a systematic review. Lancet Respir Med. 
2015; 3(3):235–243. DOI: 10.1016/S2213-2600(15)00028-4 [PubMed: 25648115] 
3. Chintu C, Mudenda V, Lucas S, et al. Lung diseases at necropsy in African children dying from 
respiratory illnesses: a descriptive necropsy study. Lancet. 2002; 360(9338):985–990. DOI: 
10.1016/S0140-6736(02)11082-8 [PubMed: 12383668] 
4. Drobac PC, Shin SS, Huamani P, et al. Risk Factors for In-Hospital Mortality Among Children With 
Tuberculosis: The 25-Year Experience in Peru. Pediatrics. 2012; 130(2):e373–e379. DOI: 10.1542/
peds.2011-3048 [PubMed: 22826566] 
5. Starke JR, Taylor-Watts KT. Tuberculosis in the Pediatric Population of Houston, Texas. Pediatrics. 
1989; 84(1):28–35. [PubMed: 2500637] 
6. Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in 
children: systematic review and global estimates. Lancet. 2014; 383:1572–1579. DOI: 10.1016/
S0140-6736(14)60195-1 [PubMed: 24671080] 
7. World Health Organization. Global Tuberculosis Report 2012. Geneva, Switzerland: 2012. 
8. Starke JR. Tuberculosis in children. Seminars in respiratory and critical care medicine. 2004; 25(3):
353–364. DOI: 10.1055/s-2004-829507 [PubMed: 16088476] 
9. Perez-Velez CM, Marais BJ. Tuberculosis in Children. N Engl J Med. 2012; 367(4):348–361. DOI: 
10.1056/NEJMra1008049 [PubMed: 22830465] 
10. Mukadi YD, Wiktor SZ, Coulibaly I-M, et al. Impact of HIV infection on the development, clinical 
presentation, and outcome of tuberculosis among children in Abidjan, Côte d’Ivoire. AIDS. 1997; 
11(9):1151–1158. [PubMed: 9233463] 
11. Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R. Impact of HIV infection on the 
epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific 
interventions. Clin Inf Dis. 2006; 42:1040–1047.
12. Davidson RN. Childhood tuberculosis—problems ahead. Trans R Soc Trop Med Hyg. 2000; 94(1):
5–6. DOI: 10.1016/S0035-9203(00)90415-2 [PubMed: 10748885] 
13. Harries AD, Hargreaves NJ, Graham SM. Childhood tuberculosis in Malawi: nationwide case-
finding and treatment outcomes. Int J Tuberc Lung Dis. 2002; 6(5):424–431. [PubMed: 12019918] 
14. Malawi National Statistical Office. 2014 Malawi Population. Zomba, Malawi: 2014. 
15. Malawi National Statistical Office, ICF Macro. Malawi Demographic and Health Survey 2010. 
Zomba, Malawi and Calverton, Maryland, USA: 2011. 
16. Ahmed S, Kim MH, Dave AC, et al. Improved identification and enrolment into care of HIV-
exposed and -infected infants and children following a community health worker intervention in 
Lilongwe, Malawi. J Int AIDS Soc. 2015; 18(1)doi: 10.7448/IAS.18.1.19305
17. Kim MH, Ahmed S, Buck WC, et al. The Tingathe programme: a pilot intervention using 
community health workers to create a continuum of care in the prevention of mother to child 
transmission of HIV (PMTCT) cascade of services in Malawi. J Int AIDS Soc. 2012; 15 Suppl 
2(4)doi: 10.7448/IAS.15.4.17389
18. UNAIDS. World Gap Report 2014. Geneva, Switzerland: 2014. 
19. World Health Organization. Global Tuberculosis Report 2015. Geneva, Switzerland: 2015. 
20. Government of Malawi Ministry of Health. Malawi National Tuberculosis Control Programme 
Manual. 7. 2012. 
21. World Health Organization. Treatment of Tuberculosis Guidelines. 4. Geneva, Switzerland: 2010. 
Flick et al. Page 9
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2017 February 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
22. Malawi National Statistical Office. Unpublished semipermanent data. 2015. 
23. Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden 
countries: a mathematical modelling study. Lancet Glob Health. Jul.2014 doi: 10.1016/
S2214-109X(14)70245-1
24. United States Central Intelligence Agency. [Accessed 17 November 2015] World Factbook 1998. 
http://www.umsl.edu/services/govdocs/wofact98/4.htm
25. United States Central Intelligence Agency. [Accessed 17 November 2015] World Factbook. 2015. 
https://www.cia.gov/library/publications/the-world-factbook/
26. Ahmed S, Schwarz M, Flick R, et al. Lost opportunities to identify and treat HIV-positive patients: 
results from a baseline assessment of provider-initiated HIV testing and counseling in Malawi. 
Trop Med Int Health. Jan.2016 doi: 10.1111/tmi.12671
27. Kanyerere H, Mganga A, Harries AD, et al. Decline in adverse outcomes and death in tuberculosis 
patients in Malawi: association with HIV interventions. PHA. 2015; 5(2):116–118. DOI: 10.5588/
pha.14.0109 [PubMed: 26400381] 
28. Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a 
diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis. 2009; 
48(6):829–831. DOI: 10.1086/597098 [PubMed: 19207078] 
29. Havlir DV, Kendall MA, Ive P, et al. Timing of Antiretroviral Therapy for HIV-1 Infection and 
Tuberculosis. N Engl J Med. 2011; 365(16):1482–1491. DOI: 10.1056/NEJMoa1013607 
[PubMed: 22010914] 
30. Davies M-A, Moultrie H, Eley B, et al. Virologic Failure and Second-Line Antiretroviral Therapy 
in Children in South Africa—The IeDEA Southern Africa Collaboration. JAIDS. 2011; 56(3):270–
278. DOI: 10.1097/QAI.0b013e3182060610 [PubMed: 21107266] 
31. Emmett SD, Cunningham CK, Mmbaga BT, et al. Predicting Virologic Failure Among HIV-1-
Infected Children Receiving Antiretroviral Therapy in Tanzania: a Cross-Sectional Study. JAIDS. 
2010; 54(4):368–375. DOI: 10.1097/QAI.0b013e3181cf4882 [PubMed: 20216225] 
32. Dow DE, Shayo AM, Cunningham CK, Reddy EA. Durability of antiretroviral therapy and 
predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year 
follow-up. Nov.2014 :1–9. DOI: 10.1186/s12879-014-0567-3
33. The TEMPRANO ANRS 12136 Study Group. A Trial of Early Antiretrovirals and Isoniazid 
Preventive Therapy in Africa. N Engl J Med. 2015; 373(9):808–822. DOI: 10.1056/
NEJMoa1507198 [PubMed: 26193126] 
34. Buck WC, Olson D, Kabue MM, et al. Risk factors for mortality in Malawian children with human 
immunodeficiency virus and tuberculosis co-infection. Int J Tuberc Lung Dis. 2013; 17(11):1389–
1395. DOI: 10.5588/ijtld.13.0030 [PubMed: 24125439] 
35. Lestari T, Probandari A, Hurtig A-K, Utarini A. High caseload of childhood tuberculosis in 
hospitals on Java Island, Indonesia: a cross sectional study. BMC Public Health. 2011; 11(1):784–
787. DOI: 10.1186/1471-2458-11-784 [PubMed: 21985569] 
36. Kim, MH., Ahmed, S., Preidis, GA., et al. Low Rates of Mother-to-Child HIV Transmission in a 
Routine Programmatic Setting in Lilongwe, Malawi. In: Jhaveri, R., editor. PLoS ONE. Vol. 8. 
2013. p. e64979
Flick et al. Page 10
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2017 February 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Overview of outcome analyses*
ATT denotes anti-TB treatment
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Figure 2. 
Pediatric case load and rate of bacteriological confirmation of tuberculosis over time
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Figure 3. 
Kaplan-Meier survival curve describing HIV-infected children according to ARV status
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Table 1
Age-specific annual incidence rates of tuberculosis in 2012
Age group Reported TB cases during 2012 Population at risk 1 January 201222
Age group-specific incidence rate per 100,000 
population
<1 12 28,475 42
1–4 49 113,902 43
5–15 138 213,566 65
<15 199 355,943 56
>15 1,912 385,605 496
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Table 3
Anatomic site of involvement for 144 patients with extrapulmonary TB*
Site n (%)
Lymph nodes 53 (36.8)
Pleura 30 (20.8)
Vertebrae 24 (16.7)
Pericardium 23 (16.0)
Ascites 9 (6.3)
Meningitis 2 (1.4)
Osseous† 2 (1.4)
Empyema 1(0.7)
*13 patients missing documentation of site
†
Excluding vertebral
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